CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Funding Request||In combination with paclitaxel and carboplatin for the front-line treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high risk of relapse (stage III sub-optimally debulked, or stage III unresectable, or stage IV patients|
|Pre Noc Submission||Yes|
|Manufacturer||Hoffmann-La Roche Limited|
|Sponsor||Hoffmann-La Roche Limited|
|Submission Date||November 28, 2014|
|Submission Deemed Complete||December 5, 2014|
|Prioritization Requested||Requested and Not Granted|
|Stakeholder Input Deadline ‡||December 12, 2014|
|Check-point meeting||January 26, 2015|
|pERC Meeting||March 19, 2015|
|Initial Recommendation Issued||April 2, 2015|
|Feedback Deadline ‡||April 17, 2015|
|pERC Reconsideration Meeting||May 21, 2015|
|Final Recommendation Issued||June 4, 2015|
|Notification to Implement Issued||June 19, 2015|
|Therapeutic Area||Ovarian Cancer|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.